DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Silver Spring MD 20993

NDA 50-689/S-022

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Shai Srulovich, PharmD, RPh
Senior Manager, Worldwide Safety & Regulatory
235 East 42nd Street
New York, NY 10017

Dear Dr. Srulovich:

Please refer to your Supplemental New Drug Application (sNDA) dated October 3, 2014,
received October 3, 2014, submitted under section 505(b) of the Federal Food, Drug, and
Cosmetic Act (FDCA) for Mycobutin (rifabutin) Capsules.

We acknowledge receipt of your amendments dated January 7, February 4, May 14 and June 5,
2015.

This “Prior Approval” supplemental new drug application proposes to clarify the use of the term
“shock” in the ADVERSE REACTIONS section of the label.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved,
effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling
text and with the minor editorial revisions listed below and indicated in the enclosed labeling.

Under the ADVERSE REACTIONS section, in the CLINICAL ADVERSE EVENTS
REPORTED IN <1% OF PATIENTS WHO RECEIVED MYCOBUTIN subsection,
Immune system disorders should read as follows:

“Immune system disorders: Hypersensitivity, bronchospasm, rash and eosinophilia”

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of
labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
automated drug registration and listing system (eLIST), as described at
of labeling must be identical to, except with the revisions listed in the letter and indicated in the
enclosed labeling text for the package insert with the addition of any labeling changes in pending

Reference ID: 3786597
“Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions indicated above and in the attached label approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carmen DeBellas, Regulatory Project Manager, at (301) 796-1203.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
07/01/2015

Reference ID: 3786597